BR112022012470A2 - Proteína rsv f mutante e uso da mesma - Google Patents

Proteína rsv f mutante e uso da mesma

Info

Publication number
BR112022012470A2
BR112022012470A2 BR112022012470A BR112022012470A BR112022012470A2 BR 112022012470 A2 BR112022012470 A2 BR 112022012470A2 BR 112022012470 A BR112022012470 A BR 112022012470A BR 112022012470 A BR112022012470 A BR 112022012470A BR 112022012470 A2 BR112022012470 A2 BR 112022012470A2
Authority
BR
Brazil
Prior art keywords
leucine
mutation
amino acid
rsv
protein
Prior art date
Application number
BR112022012470A
Other languages
English (en)
Inventor
Hogiri Tomoharu
Kishida Hiroyuki
Takedomi Kei
Branduardi Davide
Oloo Eliud
Feyfant Eric
Ichihara Osamu
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of BR112022012470A2 publication Critical patent/BR112022012470A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18523—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18571—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

PROTEÍNA RSV F MUTANTE E USO DA MESMA. A presente invenção provê uma proteína RSV F mutante tendo uma mutação, em que a mutação é uma substituição de uma leucina correspondendo a uma leucina na posição 141 de uma sequência de aminoácido da SEQ ID Nº: 1 ou uma leucina correspondendo a uma leucina na posição 142 com uma cisteína e uma substituição de uma leucina correspondendo a uma leucina na posição 373 com uma cisteína, e uma ligação de bissulfeto é formada entre as cisteínas. Ainda é provida uma proteína RSV F mutante tendo uma mutação, em que a mutação é uma substituição de um ácido glutâmico correspondendo a um ácido glutâmico na posição 60 da sequência de aminoácido da SEQ ID Nº: 1 com um aminoácido não ácido.
BR112022012470A 2019-12-23 2020-12-23 Proteína rsv f mutante e uso da mesma BR112022012470A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962952673P 2019-12-23 2019-12-23
PCT/JP2020/048254 WO2021132379A1 (ja) 2019-12-23 2020-12-23 変異型ｒｓｖ ｆタンパク質及びその利用

Publications (1)

Publication Number Publication Date
BR112022012470A2 true BR112022012470A2 (pt) 2022-09-06

Family

ID=76574266

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022012470A BR112022012470A2 (pt) 2019-12-23 2020-12-23 Proteína rsv f mutante e uso da mesma

Country Status (13)

Country Link
US (1) US20230086093A1 (pt)
EP (1) EP4083212A4 (pt)
JP (2) JP7385680B2 (pt)
KR (1) KR20220116516A (pt)
CN (1) CN114929877A (pt)
AR (1) AR120891A1 (pt)
AU (1) AU2020411873B2 (pt)
BR (1) BR112022012470A2 (pt)
CA (1) CA3165855A1 (pt)
IL (1) IL294059A (pt)
MX (1) MX2022007881A (pt)
TW (1) TW202130363A (pt)
WO (1) WO2021132379A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117715923A (zh) * 2022-04-29 2024-03-15 北京新合睿恩生物医疗科技有限公司 Rsv f蛋白突变体及其应用
CN118108812A (zh) * 2023-05-04 2024-05-31 国药中生生物技术研究院有限公司 Rsv f蛋白的突变体
CN117487823A (zh) * 2023-09-28 2024-02-02 怡道生物科技(苏州)有限公司 呼吸道合胞体病毒mRNA疫苗及其制备方法和应用
CN117586359A (zh) * 2024-01-19 2024-02-23 北京安百胜生物科技有限公司 一种具有免疫原性的呼吸道合胞病毒（rsv）多肽
CN117586358B (zh) * 2024-01-19 2024-08-13 北京安百胜生物科技有限公司 一种具有免疫原性的呼吸道合胞病毒（rsv）多肽

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4212921B2 (ja) 2002-03-29 2009-01-21 独立行政法人科学技術振興機構 抗体を提示するタンパク質中空ナノ粒子を用いる治療薬剤およびタンパク質中空ナノ粒子
WO2014160463A1 (en) 2013-03-13 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prefusion rsv f proteins and their use
RU2723039C2 (ru) * 2015-12-23 2020-06-08 Пфайзер Инк. Мутанты белка f rsv
AU2017242020B2 (en) 2016-03-29 2021-08-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Substitutions-modified prefusion RSV F proteins and their use

Also Published As

Publication number Publication date
AR120891A1 (es) 2022-03-30
CA3165855A1 (en) 2021-07-01
TW202130363A (zh) 2021-08-16
IL294059A (en) 2022-08-01
US20230086093A1 (en) 2023-03-23
EP4083212A4 (en) 2024-03-27
JP2024016234A (ja) 2024-02-06
AU2020411873B2 (en) 2024-07-25
JP7385680B2 (ja) 2023-11-22
CN114929877A (zh) 2022-08-19
JPWO2021132379A1 (pt) 2021-07-01
KR20220116516A (ko) 2022-08-23
WO2021132379A1 (ja) 2021-07-01
MX2022007881A (es) 2022-07-19
EP4083212A1 (en) 2022-11-02
AU2020411873A1 (en) 2022-07-28

Similar Documents

Publication Publication Date Title
BR112022012470A2 (pt) Proteína rsv f mutante e uso da mesma
PE20120358A1 (es) Mutantes fgf21 y usos de los mismos
BR0313429A (pt) peptìdeos como excipientes solubilizantes para proteìnas do fator de crescimento beta de transformação
HRP20090245T1 (en) Pyy agonists and uses thereof
DE502005006284D1 (de) Keratin-bindende polypeptide
CY1111411T1 (el) Αναλογα του παρομοιου-με-την-γλυκαγονη-πεπτιδιου-2(glp-2)
CY1113218T1 (el) Υβριδιο και διμερης εκφραση πρωτεϊνων ναϊσσεριας
NO974270L (no) Insulinderivater
BR112021023957A2 (pt) Peptídeos
BR112018003594A2 (pt) cadeia pesada de imunoglobulina recombinante, anticorpos, método de produção de conjugado e conjugados
EA202190264A1 (ru) КОМПОЗИЦИИ АНТИТЕЛ ПРОТИВ FcRn
BR112013013548B8 (pt) Proteína de fusão anticancerígena
PL415888A1 (pl) Sposób wytwarzania insuliny i jej pochodnych oraz peptyd hybrydowy stosowany w tym sposobie
ATE405654T1 (de) Polypeptid mit verbesserter cytosin-deaminase- aktivität
BR112017017609A2 (pt) proteína de fusão fc, e, composição farmacêutica.
BRPI0507186A (pt) composição, métodos e usos para uma nova famìlia de peptìdeos
DE60335726D1 (de) Chromoprotein und fluoroproteine
WO2018130212A3 (zh) 胃蛋白抗性改良和催化效率提高的植酸酶YkAPPA突变体
BRPI0715331B8 (pt) polipeptídeo que compreende uma porção n-terminal e uma porção c-terminal, e uso do mesmo
CO2020016749A2 (es) Proteína novedosa con propiedades antiinflamatorias
BR112022007729A2 (pt) Polipeptídeo tendo efeito mmp2-inibidor
EA202092963A1 (ru) Новый белок с противовоспалительными свойствами
MX2021011407A (es) Proteinas de dominio ccn recombinantes y proteinas de fusion.
NO20081503L (no) T-celle adhesjonsmolekyl, og antistoff dertil
WO2020162684A3 (ko) 신규의 oct-3/4 변이체